MedPath
Found 1 clinical trials|View Analysis
Sort by:

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2
Recruiting
Conditions
Post-Transplant Lymphoproliferative Disorder
Refractory Mantle Cell Lymphoma
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Interventions
First Posted Date
2022-07-12
Last Posted Date
2024-10-17
Lead Sponsor
University of Washington
Target Recruit Count
40
Registration Number
NCT05453396
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath